Dr. Ben Hatano, MD, PhDHead of Clinical Science at GenmabSpeaker
Profile
Dr. Ben Hatano, MD, PhD, MBA, is an accomplished oncology and immunology expert with extensive experience in clinical development and medical affairs. With a PhD in Surgical Pathology from Fukuoka University and an MBA from the Kenichi Ohmae Graduate School of Business, Dr. Hatano excels in aligning strategic plans with global development strategies.
Currently, as the Head of Clinical Science at Genmab in Japan, he leads groundbreaking oncology treatments, enhancing team capabilities and driving successful project execution. Previously, at BMS, Celgene and Novartis, Dr. Hatano led numerous clinical trials and facilitated approvals of key immunology and oncology therapies.
With a postdoctoral fellowship at Harvard School of Public Health, Dr. Hatano's academic tenure included advanced research in metabolic diseases. Recognized for his leadership, he has contributed to over 40 peer-reviewed publications and high-impact clinical protocols, shaping the future of medical treatment through innovation and patient care in the pharmaceutical industry.
Agenda Sessions
Development Overview of Bispecific DuoBody®-PD-L1×4-1BB (Acasunlimab): Next Generation Cancer Immunotherapy
, 11:15View Session